1. Search Result
Search Result
Results for "

bleomycin-induced mouse lung fibrosis

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147936

    MMP Inflammation/Immunology
    TP0556351 is a potent and selective matrix metalloproteinase-2 (MMP2) inhibitor with an IC50 value of 0.2 nM. TP0556351 reduces the amount of collagen in the lungs of a Bleomycin-induced pulmonary fibrosis mouse model. TP0556351 can be used for researching idiopathic pulmonary fibrosis (IPF) .
    TP0556351
  • HY-181741

    Cathepsin Inflammation/Immunology
    PI3K-001 is a cathepsin B-responsive prodrug and antifibrotic agent. PI3K-001 undergoes cathepsin B-mediated cleavage of the Val-Ala linker in fibrotic lung lesions to release an active PI3K inhibitor payload, while it remains stable in healthy tissues. PI3K-001 improves collagen deposition, tissue collapse and alveolar injury in fibrotic lung tissues. PI3K-001 is applicable for the research of pulmonary fibrosis .
    PI3K-001
  • HY-181931

    Phosphodiesterase (PDE) p38 MAPK LPL Receptor ERK JNK Inflammation/Immunology
    Autotaxin-IN-8 (Compound 14E) is an orally active Autotaxin inhibitor with an IC50 of 14.2 nM against hAutotaxin. Autotaxin-IN-8 inhibits Autotaxin activity, MAPK activation, LPAR1 and p-ERK1/2. Autotaxin-IN-8 reduces the phosphorylation levels of JNK and p38. Autotaxin-IN-8 decreases collagen deposition in a mouse model of pulmonary fibrosis. Autotaxin-IN-8 can be used in research related to pulmonary fibrosis .
    Autotaxin-IN-8
  • HY-184278

    Phosphodiesterase (PDE) Inflammation/Immunology
    ATX-IN-28 is an orally active autotaxin (ATX) inhibitor with an IC50 of 13.7 nM. ATX-IN-28 downregulates the expression of pro-fibrotic α-SMA, ameliorates pathological damage of lung tissues in a bleomycin (HY-108345)-induced mouse model of pulmonary fibrosis, and reduces collagen deposition. ATX-IN-28 can be used for research related to idiopathic pulmonary fibrosis .
    ATX-IN-28
  • HY-181884

    Inflammation/Immunology
    TLR9-IN-3 is a TLR9 antagonist with an IC50 of 0.4 μM. TLR9-IN-3 shows selectivity for TLR4 and TLR8, and inhibits CD69 activation in human whole blood with a corresponding IC50 of 1.1 μM. TLR9-IN-3 can be used in research related to pulmonary fibrosis .
    TLR9-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: